Andrew Morris - SQI Diagnostics CEO and President and Director
| SQIDFDelisted Stock | USD 0.01 0.00 0.00% |
CEO
Mr. Andrew Morris is President, Chief Executive Officer, Director of SQI Diagnostics Inc., since April 2007. He joined the SQI Diagnostics team in 2004 with the key deliverables of growing and enhancing the Company financial position and corporate strategy. Andrew adds a wellrounded experience set gained in leadership roles in the areas of medical research, capital markets and corporate finance. Prior to joining SQI, Andrew led the Corporationrationrate Finance Life Sciences group at Ernst Young, advising private and public companies on a variety of business strategy and financial matters including private equity offerings, mergers and acquisitions, and strategic alliances. Prior to that, Andrew gained considerable transaction experience while working in senior corporate development and finance roles in high growth and startup companies. He also gained capital markets and equity research experience at Scotia Capital, while covering companies in the Healthcare and Biotechnology sector. Andrew background also includes eight years conducting research in the area of human performance enhancement at the Defence and Civil Institute of Environmental Medicine. He holds an Honours BS from the University of Western Ontario, a MS from the Faculty of Medicine at the University of Toronto, and a MBA degree from the Rotman School of Management at the University of Toronto. With experience in turning around, shaping and building companies, this team forms the optimum executive roster to propel SQI Diagnostics forward. since 2013.
| Age | 57 |
| Tenure | 11 years |
| Phone | 416 674 9500 |
| Web | https://www.sqidiagnostics.com |
SQI Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.9421) % which means that it has lost $0.9421 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.5407) %, meaning that it generated substantial loss on money invested by shareholders. SQI Diagnostics' management efficiency ratios could be used to measure how well SQI Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.SQI Diagnostics has accumulated 6.3 M in total debt with debt to equity ratio (D/E) of 4.64, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SQI Diagnostics has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist SQI Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, SQI Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SQI Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SQI to invest in growth at high rates of return. When we think about SQI Diagnostics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CEO Age | ||
| Hamid Erfanian | Enzo Biochem | 54 | |
| Scott Hutton | Biodesix | 52 | |
| Peter Maag | Caredx Inc | 57 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
| Steven Chapman | Natera Inc | 45 | |
| BSc III | T2 Biosystms | 61 | |
| John Hanna | Caredx Inc | 44 | |
| Jacob Thaysen | Illumina | 49 | |
| Harry Simeonidis | Intelligent Bio Solutions | 56 | |
Management Performance
| Return On Equity | -12.54 | |||
| Return On Asset | -0.94 |
SQI Diagnostics Leadership Team
Elected by the shareholders, the SQI Diagnostics' board of directors comprises two types of representatives: SQI Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SQI. The board's role is to monitor SQI Diagnostics' management team and ensure that shareholders' interests are well served. SQI Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SQI Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Morris, CEO and President and Director | ||
| Russell Peloquin, VP Operations | ||
| Eric Brouwer, Chief Scientific Officer | ||
| CFA CPA, CFO Admin | ||
| Peter Lea, Founder | ||
| Tim McGough, Chief Officer |
SQI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is SQI Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.54 | |||
| Return On Asset | -0.94 | |||
| Profit Margin | (2.29) % | |||
| Operating Margin | (1.71) % | |||
| Current Valuation | 34.24 M | |||
| Shares Outstanding | 406.25 M | |||
| Shares Owned By Insiders | 51.02 % | |||
| Shares Owned By Institutions | 24.31 % | |||
| Price To Earning | (2.35) X | |||
| Price To Book | 16.12 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in SQI Pink Sheet
If you are still planning to invest in SQI Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SQI Diagnostics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Directory Find actively traded commodities issued by global exchanges |